A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2021-04-14

AUTHORS

Gerald S. Falchook, Marc Peeters, Sylvie Rottey, Luc Y. Dirix, Radka Obermannova, Jonathan E. Cohen, Ruth Perets, Ronnie Shapira Frommer, Todd M. Bauer, Judy S. Wang, Richard D. Carvajal, Joshua Sabari, Sonya Chapman, Wei Zhang, Boris Calderon, Daniel A. Peterson

ABSTRACT

Background LY3022855 is a recombinant, immunoglobulin, human monoclonal antibody targeting the colony-stimulating factor-1 receptor. This phase 1 trial determined the safety, pharmacokinetics, and antitumor activity of LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid cancers who had received standard anti-cancer treatments. Methods In Part A (dose-escalation), patients received intravenous (IV) LY3022855 25/50/75/100 mg once weekly (QW) combined with durvalumab 750 mg once every two weeks (Q2W) IV or LY3022855 50 or 100 mg QW IV with tremelimumab 75/225/750 mg once every four weeks. In Part B (dose-expansion), patients with non-small cell lung cancer (NSCLC) or ovarian cancer (OC) received recommended phase 2 dose (RP2D) of LY3022855 from Part A and durvalumab 750 mg Q2W. Results Seventy-two patients were enrolled (median age 61 years): Part A = 33, Part B = 39. In Part A, maximum tolerated dose was not reached, and LY3022855 100 mg QW and durvalumab 750 mg Q2W was the RP2D. Four dose-limiting equivalent toxicities occurred in two patients from OC cohort. In Part A, maximum concentration, area under the concentration-time curve, and serum concentration showed dose-dependent increase over two cycles of therapy. Overall rates of complete response, partial response, and disease control were 1.4%, 2.8%, and 33.3%. Treatment-emergent anti-drug antibodies were observed in 21.2% of patients. Conclusions LY3022855 combined with durvalumab or tremelimumab in patients with advanced NSCLC or OC had limited clinical activity, was well tolerated. The RP2D was LY3022855 100 mg QW with durvalumab 750 mg Q2W. ClinicalTrials.gov ID: NCT02718911 (Registration Date: May 3, 2011). More... »

PAGES

1284-1297

Journal

TITLE

Investigational New Drugs

ISSUE

5

VOLUME

39

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-021-01088-4

DOI

http://dx.doi.org/10.1007/s10637-021-01088-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1137196840

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33852104


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ovarian Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Colony-Stimulating Factor", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Drug Development Unit, Sarah Cannon Research Institute at HealthONE, 1800 Williams St Ste 300, Denver, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.489173.0", 
          "name": [
            "Drug Development Unit, Sarah Cannon Research Institute at HealthONE, 1800 Williams St Ste 300, Denver, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Falchook", 
        "givenName": "Gerald S.", 
        "id": "sg:person.0754516716.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754516716.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, University Antwerpen, Universitair Ziekenhuis Antwerpen, Drie Eikenstraat, Edegem, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.411414.5", 
          "name": [
            "Department of Oncology, University Antwerpen, Universitair Ziekenhuis Antwerpen, Drie Eikenstraat, Edegem, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peeters", 
        "givenName": "Marc", 
        "id": "sg:person.07540360642.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07540360642.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Drug Research Unit, Universitair Ziekenhuis Gent, Corneel Heymanslaan, Ghent, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.410566.0", 
          "name": [
            "Drug Research Unit, Universitair Ziekenhuis Gent, Corneel Heymanslaan, Ghent, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rottey", 
        "givenName": "Sylvie", 
        "id": "sg:person.0742751333.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742751333.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, GZA Sint Augustinus, Oosterveldlaan, Wilrijk, Belgium", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Medical Oncology, GZA Sint Augustinus, Oosterveldlaan, Wilrijk, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dirix", 
        "givenName": "Luc Y.", 
        "id": "sg:person.0723122133.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723122133.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Comprehensive Cancer Care Department \u2013 Faculty of Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic", 
          "id": "http://www.grid.ac/institutes/grid.419466.8", 
          "name": [
            "Comprehensive Cancer Care Department \u2013 Faculty of Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Obermannova", 
        "givenName": "Radka", 
        "id": "sg:person.01367614272.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367614272.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Faculty of Medicine, The Wohl Institute for Translational Medicine, Hadassah Medical Center, Jerusalem, Israel", 
          "id": "http://www.grid.ac/institutes/grid.17788.31", 
          "name": [
            "Department of Oncology, Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel", 
            "The Faculty of Medicine, The Wohl Institute for Translational Medicine, Hadassah Medical Center, Jerusalem, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Jonathan E.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Technion \u2013 Israel Institute of Technology, Haifa, Israel", 
          "id": "http://www.grid.ac/institutes/grid.6451.6", 
          "name": [
            "Department of Oncology, Clinical Research Institute at Rambam, Rambam Medical Center, Haifa, Israel", 
            "Technion \u2013 Israel Institute of Technology, Haifa, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Perets", 
        "givenName": "Ruth", 
        "id": "sg:person.01037224711.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037224711.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Ella Institute for Immuno-Oncology, Sheba Medical Center, Oncology Institute, Tel Hashomer, Ramat Gan, Israel", 
          "id": "http://www.grid.ac/institutes/grid.413795.d", 
          "name": [
            "The Ella Institute for Immuno-Oncology, Sheba Medical Center, Oncology Institute, Tel Hashomer, Ramat Gan, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Frommer", 
        "givenName": "Ronnie Shapira", 
        "id": "sg:person.015171664337.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015171664337.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.492963.3", 
          "name": [
            "Department of Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bauer", 
        "givenName": "Todd M.", 
        "id": "sg:person.01343430002.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343430002.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hematologic Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA", 
          "id": "http://www.grid.ac/institutes/grid.428633.8", 
          "name": [
            "Hematologic Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Judy S.", 
        "id": "sg:person.011344020557.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011344020557.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.21729.3f", 
          "name": [
            "Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine,Medical Oncology, NYU Langone Health, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.240324.3", 
          "name": [
            "Department of Medicine,Medical Oncology, NYU Langone Health, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sabari", 
        "givenName": "Joshua", 
        "id": "sg:person.011553707331.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011553707331.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Windlesham, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.418786.4", 
          "name": [
            "Eli Lilly and Company, Windlesham, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chapman", 
        "givenName": "Sonya", 
        "id": "sg:person.07541362455.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07541362455.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Wei", 
        "id": "sg:person.07670550366.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07670550366.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calderon", 
        "givenName": "Boris", 
        "id": "sg:person.016577377627.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016577377627.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peterson", 
        "givenName": "Daniel A.", 
        "id": "sg:person.012332515531.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012332515531.79"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s13046-019-1409-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1120996560", 
          "https://doi.org/10.1186/s13046-019-1409-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-017-0257-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090453966", 
          "https://doi.org/10.1186/s40425-017-0257-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-018-0435-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109887636", 
          "https://doi.org/10.1186/s40425-018-0435-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41598-017-18433-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100203108", 
          "https://doi.org/10.1038/s41598-017-18433-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13046-019-1357-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1120498622", 
          "https://doi.org/10.1186/s13046-019-1357-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11596370-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002877462", 
          "https://doi.org/10.2165/11596370-000000000-00000"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-04-14", 
    "datePublishedReg": "2021-04-14", 
    "description": "Background LY3022855 is a recombinant, immunoglobulin, human monoclonal antibody targeting the colony-stimulating factor-1 receptor. This phase 1 trial determined the safety, pharmacokinetics, and antitumor activity of LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid cancers who had received standard anti-cancer treatments. Methods In Part A (dose-escalation), patients received intravenous (IV) LY3022855 25/50/75/100\u00a0mg once weekly (QW) combined with durvalumab 750\u00a0mg once every two weeks (Q2W) IV or LY3022855 50 or 100\u00a0mg QW IV with tremelimumab 75/225/750\u00a0mg once every four weeks. In Part B (dose-expansion), patients with non-small cell lung cancer (NSCLC) or ovarian cancer (OC) received recommended phase 2 dose (RP2D) of LY3022855 from Part A and durvalumab 750\u00a0mg Q2W. Results Seventy-two patients were enrolled (median age 61\u00a0years): Part A\u2009=\u200933, Part B\u2009=\u200939. In Part A, maximum tolerated dose was not reached, and LY3022855 100\u00a0mg QW and durvalumab 750\u00a0mg Q2W was the RP2D. Four dose-limiting equivalent toxicities occurred in two patients from OC cohort. In Part A, maximum concentration, area under the concentration-time curve, and serum concentration showed dose-dependent increase over two cycles of therapy. Overall rates of complete response, partial response, and disease control were 1.4%, 2.8%, and 33.3%. Treatment-emergent anti-drug antibodies were observed in 21.2% of patients. Conclusions LY3022855 combined with durvalumab or tremelimumab in patients with advanced NSCLC or OC had limited clinical activity, was well tolerated. The RP2D was LY3022855 100\u00a0mg QW with durvalumab 750\u00a0mg Q2W. ClinicalTrials.gov ID: NCT02718911 (Registration Date: May 3, 2011).", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-021-01088-4", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "keywords": [
      "non-small cell lung cancer", 
      "ovarian cancer", 
      "advanced non-small cell lung cancer", 
      "treatment-emergent anti-drug antibodies", 
      "recommended phase 2 dose", 
      "standard anti-cancer treatments", 
      "phase 2 dose", 
      "cycles of therapy", 
      "advanced solid cancers", 
      "advanced solid tumors", 
      "phase 1 trial", 
      "cell lung cancer", 
      "anti-drug antibodies", 
      "concentration-time curve", 
      "dose-dependent increase", 
      "human monoclonal antibody", 
      "anti-cancer treatment", 
      "Part A", 
      "factor 1 receptor", 
      "partial response", 
      "colony-stimulating factor 1 receptor", 
      "complete response", 
      "OC cohort", 
      "lung cancer", 
      "serum concentrations", 
      "Results Seventy", 
      "clinical activity", 
      "solid cancers", 
      "patients", 
      "solid tumors", 
      "durvalumab", 
      "tremelimumab", 
      "disease control", 
      "monoclonal antibodies", 
      "week IV", 
      "antitumor activity", 
      "cancer", 
      "Part B", 
      "Q2W.", 
      "overall rate", 
      "dose", 
      "trials", 
      "antibodies", 
      "equivalent toxicity", 
      "Q2W", 
      "RP2D.", 
      "RP2D", 
      "maximum concentration", 
      "pharmacokinetics", 
      "therapy", 
      "cohort", 
      "tumors", 
      "weeks", 
      "receptors", 
      "response", 
      "treatment", 
      "activity", 
      "toxicity", 
      "safety", 
      "concentration", 
      "combination", 
      "control", 
      "rate", 
      "increase", 
      "recombinants", 
      "seventies", 
      "curves", 
      "area", 
      "ID", 
      "cycle", 
      "method", 
      "QW"
    ], 
    "name": "A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors", 
    "pagination": "1284-1297", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1137196840"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-021-01088-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33852104"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-021-01088-4", 
      "https://app.dimensions.ai/details/publication/pub.1137196840"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_893.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-021-01088-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-021-01088-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-021-01088-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-021-01088-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-021-01088-4'


 

This table displays all metadata directly associated to this object as RDF triples.

374 TRIPLES      21 PREDICATES      121 URIs      107 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-021-01088-4 schema:about N1183bf283b7b4c60ae409ce404ab2642
2 N13bbfd8fa998404f912c5521ba3d748d
3 N1bb52bf888f4471b801e2240083bf8ff
4 N2c0bd47ef5b447e9a82d6d1a9616f0cc
5 N39650ada1dc3488480765c154f01c40c
6 N701b7bc422b54077b853fa78a9a33356
7 N74c951a5814e4dbeb011468c99f34284
8 N7d3613ccc8ff41629a3cd4676790f260
9 N8f0732feea02407c96fd57a99a6a6815
10 N9018441cf01e44d4b7de45ec72144035
11 N9479c7a1d65d488895a228771ece9375
12 Na10d6956570d47049a0b601c6098922d
13 Na60fea32db304c16b7e33b1a9e30c408
14 Nc4d1d0a884d9467e930e8e80ba74ec91
15 Ncf9a31661dec46db9d2f68c9452fcfd9
16 Nd5da2d04bf1a489e86932d0d74e673aa
17 Ne3327d11b6ea4768ab3bc4dae336821a
18 Nf0e078e3066a4fc0b1bde39ad4574f22
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N9af5f9531eb145f88eebb989fe23ac56
22 schema:citation sg:pub.10.1038/s41598-017-18433-4
23 sg:pub.10.1186/s13046-019-1357-y
24 sg:pub.10.1186/s13046-019-1409-3
25 sg:pub.10.1186/s40425-017-0257-y
26 sg:pub.10.1186/s40425-018-0435-6
27 sg:pub.10.2165/11596370-000000000-00000
28 schema:datePublished 2021-04-14
29 schema:datePublishedReg 2021-04-14
30 schema:description Background LY3022855 is a recombinant, immunoglobulin, human monoclonal antibody targeting the colony-stimulating factor-1 receptor. This phase 1 trial determined the safety, pharmacokinetics, and antitumor activity of LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid cancers who had received standard anti-cancer treatments. Methods In Part A (dose-escalation), patients received intravenous (IV) LY3022855 25/50/75/100 mg once weekly (QW) combined with durvalumab 750 mg once every two weeks (Q2W) IV or LY3022855 50 or 100 mg QW IV with tremelimumab 75/225/750 mg once every four weeks. In Part B (dose-expansion), patients with non-small cell lung cancer (NSCLC) or ovarian cancer (OC) received recommended phase 2 dose (RP2D) of LY3022855 from Part A and durvalumab 750 mg Q2W. Results Seventy-two patients were enrolled (median age 61 years): Part A = 33, Part B = 39. In Part A, maximum tolerated dose was not reached, and LY3022855 100 mg QW and durvalumab 750 mg Q2W was the RP2D. Four dose-limiting equivalent toxicities occurred in two patients from OC cohort. In Part A, maximum concentration, area under the concentration-time curve, and serum concentration showed dose-dependent increase over two cycles of therapy. Overall rates of complete response, partial response, and disease control were 1.4%, 2.8%, and 33.3%. Treatment-emergent anti-drug antibodies were observed in 21.2% of patients. Conclusions LY3022855 combined with durvalumab or tremelimumab in patients with advanced NSCLC or OC had limited clinical activity, was well tolerated. The RP2D was LY3022855 100 mg QW with durvalumab 750 mg Q2W. ClinicalTrials.gov ID: NCT02718911 (Registration Date: May 3, 2011).
31 schema:genre article
32 schema:isAccessibleForFree false
33 schema:isPartOf N5b543469a9a647a8acafc2dd5fe33fab
34 N6e8ad6fdf14145aba3a384fb06232bd3
35 sg:journal.1094201
36 schema:keywords ID
37 OC cohort
38 Part A
39 Part B
40 Q2W
41 Q2W.
42 QW
43 RP2D
44 RP2D.
45 Results Seventy
46 activity
47 advanced non-small cell lung cancer
48 advanced solid cancers
49 advanced solid tumors
50 anti-cancer treatment
51 anti-drug antibodies
52 antibodies
53 antitumor activity
54 area
55 cancer
56 cell lung cancer
57 clinical activity
58 cohort
59 colony-stimulating factor 1 receptor
60 combination
61 complete response
62 concentration
63 concentration-time curve
64 control
65 curves
66 cycle
67 cycles of therapy
68 disease control
69 dose
70 dose-dependent increase
71 durvalumab
72 equivalent toxicity
73 factor 1 receptor
74 human monoclonal antibody
75 increase
76 lung cancer
77 maximum concentration
78 method
79 monoclonal antibodies
80 non-small cell lung cancer
81 ovarian cancer
82 overall rate
83 partial response
84 patients
85 pharmacokinetics
86 phase 1 trial
87 phase 2 dose
88 rate
89 receptors
90 recombinants
91 recommended phase 2 dose
92 response
93 safety
94 serum concentrations
95 seventies
96 solid cancers
97 solid tumors
98 standard anti-cancer treatments
99 therapy
100 toxicity
101 treatment
102 treatment-emergent anti-drug antibodies
103 tremelimumab
104 trials
105 tumors
106 week IV
107 weeks
108 schema:name A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
109 schema:pagination 1284-1297
110 schema:productId N8092f9fbced2423face8b3ccc1322b84
111 Nd91c337e14dd4d4fbb2cb80b53de17d0
112 Nfad5757dd84e4e908a35e7dfe25e0968
113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137196840
114 https://doi.org/10.1007/s10637-021-01088-4
115 schema:sdDatePublished 2022-11-24T21:07
116 schema:sdLicense https://scigraph.springernature.com/explorer/license/
117 schema:sdPublisher N6c9dc667ec11486b9ad890a917718d16
118 schema:url https://doi.org/10.1007/s10637-021-01088-4
119 sgo:license sg:explorer/license/
120 sgo:sdDataset articles
121 rdf:type schema:ScholarlyArticle
122 N07714918458a40f9a736d82aef323ff4 rdf:first sg:person.015171664337.90
123 rdf:rest Nd57fb23d2ab44ea8a89883e4286148fe
124 N1183bf283b7b4c60ae409ce404ab2642 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Lung Neoplasms
126 rdf:type schema:DefinedTerm
127 N13bbfd8fa998404f912c5521ba3d748d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Middle Aged
129 rdf:type schema:DefinedTerm
130 N1bb52bf888f4471b801e2240083bf8ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Maximum Tolerated Dose
132 rdf:type schema:DefinedTerm
133 N2542f1f709e84204b6d30e1a92e1b157 rdf:first sg:person.016577377627.60
134 rdf:rest N7a34fced87234585a7c94f01a94112e7
135 N2c0bd47ef5b447e9a82d6d1a9616f0cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Antibodies, Monoclonal
137 rdf:type schema:DefinedTerm
138 N2c9de5f6ca954f85bb293b7d29da45e0 rdf:first sg:person.011553707331.89
139 rdf:rest N5e683ddfec444e27ab25c516f850773e
140 N39650ada1dc3488480765c154f01c40c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Ovarian Neoplasms
142 rdf:type schema:DefinedTerm
143 N53d6f224039049818673fed7bb3deb84 rdf:first sg:person.0742751333.43
144 rdf:rest N754d2d8af5e847b0be477a251d615544
145 N567a51b6628b44588f0ee4181b065024 rdf:first sg:person.011344020557.48
146 rdf:rest Nc884adeeef594c5c925cc43742d35d08
147 N5b543469a9a647a8acafc2dd5fe33fab schema:volumeNumber 39
148 rdf:type schema:PublicationVolume
149 N5e683ddfec444e27ab25c516f850773e rdf:first sg:person.07541362455.51
150 rdf:rest Nfa1a85f0fac144dc94300b1195e60c21
151 N601c667f74064faa81497cc97f7e057d rdf:first sg:person.01037224711.72
152 rdf:rest N07714918458a40f9a736d82aef323ff4
153 N6c9dc667ec11486b9ad890a917718d16 schema:name Springer Nature - SN SciGraph project
154 rdf:type schema:Organization
155 N6e8ad6fdf14145aba3a384fb06232bd3 schema:issueNumber 5
156 rdf:type schema:PublicationIssue
157 N701b7bc422b54077b853fa78a9a33356 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Female
159 rdf:type schema:DefinedTerm
160 N74c951a5814e4dbeb011468c99f34284 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Aged
162 rdf:type schema:DefinedTerm
163 N754d2d8af5e847b0be477a251d615544 rdf:first sg:person.0723122133.65
164 rdf:rest N87183cfd4859445cbd943c85c440784b
165 N75bec0d4e1644d4a8dfdbb6584c9a96f rdf:first sg:person.07540360642.41
166 rdf:rest N53d6f224039049818673fed7bb3deb84
167 N7a34fced87234585a7c94f01a94112e7 rdf:first sg:person.012332515531.79
168 rdf:rest rdf:nil
169 N7d3613ccc8ff41629a3cd4676790f260 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Carcinoma, Non-Small-Cell Lung
171 rdf:type schema:DefinedTerm
172 N8092f9fbced2423face8b3ccc1322b84 schema:name dimensions_id
173 schema:value pub.1137196840
174 rdf:type schema:PropertyValue
175 N87183cfd4859445cbd943c85c440784b rdf:first sg:person.01367614272.21
176 rdf:rest Nf8b3e1754c6e43a79c8c8bc0d020422d
177 N8f0732feea02407c96fd57a99a6a6815 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Humans
179 rdf:type schema:DefinedTerm
180 N9018441cf01e44d4b7de45ec72144035 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Antineoplastic Agents
182 rdf:type schema:DefinedTerm
183 N9479c7a1d65d488895a228771ece9375 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Aged, 80 and over
185 rdf:type schema:DefinedTerm
186 N9af5f9531eb145f88eebb989fe23ac56 rdf:first sg:person.0754516716.49
187 rdf:rest N75bec0d4e1644d4a8dfdbb6584c9a96f
188 Na10d6956570d47049a0b601c6098922d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Area Under Curve
190 rdf:type schema:DefinedTerm
191 Na60fea32db304c16b7e33b1a9e30c408 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Dose-Response Relationship, Drug
193 rdf:type schema:DefinedTerm
194 Nc4d1d0a884d9467e930e8e80ba74ec91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Antineoplastic Combined Chemotherapy Protocols
196 rdf:type schema:DefinedTerm
197 Nc884adeeef594c5c925cc43742d35d08 rdf:first sg:person.0726366600.25
198 rdf:rest N2c9de5f6ca954f85bb293b7d29da45e0
199 Ncf9a31661dec46db9d2f68c9452fcfd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Antibodies, Monoclonal, Humanized
201 rdf:type schema:DefinedTerm
202 Nd57fb23d2ab44ea8a89883e4286148fe rdf:first sg:person.01343430002.75
203 rdf:rest N567a51b6628b44588f0ee4181b065024
204 Nd5da2d04bf1a489e86932d0d74e673aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Receptors, Colony-Stimulating Factor
206 rdf:type schema:DefinedTerm
207 Nd91c337e14dd4d4fbb2cb80b53de17d0 schema:name doi
208 schema:value 10.1007/s10637-021-01088-4
209 rdf:type schema:PropertyValue
210 Ne2f6dbf580e84528835cf4885938a0ce schema:affiliation grid-institutes:grid.17788.31
211 schema:familyName Cohen
212 schema:givenName Jonathan E.
213 rdf:type schema:Person
214 Ne3327d11b6ea4768ab3bc4dae336821a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Adult
216 rdf:type schema:DefinedTerm
217 Nf0e078e3066a4fc0b1bde39ad4574f22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
218 schema:name Male
219 rdf:type schema:DefinedTerm
220 Nf8b3e1754c6e43a79c8c8bc0d020422d rdf:first Ne2f6dbf580e84528835cf4885938a0ce
221 rdf:rest N601c667f74064faa81497cc97f7e057d
222 Nfa1a85f0fac144dc94300b1195e60c21 rdf:first sg:person.07670550366.33
223 rdf:rest N2542f1f709e84204b6d30e1a92e1b157
224 Nfad5757dd84e4e908a35e7dfe25e0968 schema:name pubmed_id
225 schema:value 33852104
226 rdf:type schema:PropertyValue
227 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
228 schema:name Medical and Health Sciences
229 rdf:type schema:DefinedTerm
230 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
231 schema:name Oncology and Carcinogenesis
232 rdf:type schema:DefinedTerm
233 sg:journal.1094201 schema:issn 0167-6997
234 1573-0646
235 schema:name Investigational New Drugs
236 schema:publisher Springer Nature
237 rdf:type schema:Periodical
238 sg:person.01037224711.72 schema:affiliation grid-institutes:grid.6451.6
239 schema:familyName Perets
240 schema:givenName Ruth
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037224711.72
242 rdf:type schema:Person
243 sg:person.011344020557.48 schema:affiliation grid-institutes:grid.428633.8
244 schema:familyName Wang
245 schema:givenName Judy S.
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011344020557.48
247 rdf:type schema:Person
248 sg:person.011553707331.89 schema:affiliation grid-institutes:grid.240324.3
249 schema:familyName Sabari
250 schema:givenName Joshua
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011553707331.89
252 rdf:type schema:Person
253 sg:person.012332515531.79 schema:affiliation grid-institutes:grid.417540.3
254 schema:familyName Peterson
255 schema:givenName Daniel A.
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012332515531.79
257 rdf:type schema:Person
258 sg:person.01343430002.75 schema:affiliation grid-institutes:grid.492963.3
259 schema:familyName Bauer
260 schema:givenName Todd M.
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343430002.75
262 rdf:type schema:Person
263 sg:person.01367614272.21 schema:affiliation grid-institutes:grid.419466.8
264 schema:familyName Obermannova
265 schema:givenName Radka
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367614272.21
267 rdf:type schema:Person
268 sg:person.015171664337.90 schema:affiliation grid-institutes:grid.413795.d
269 schema:familyName Frommer
270 schema:givenName Ronnie Shapira
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015171664337.90
272 rdf:type schema:Person
273 sg:person.016577377627.60 schema:affiliation grid-institutes:grid.417540.3
274 schema:familyName Calderon
275 schema:givenName Boris
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016577377627.60
277 rdf:type schema:Person
278 sg:person.0723122133.65 schema:affiliation grid-institutes:None
279 schema:familyName Dirix
280 schema:givenName Luc Y.
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723122133.65
282 rdf:type schema:Person
283 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.21729.3f
284 schema:familyName Carvajal
285 schema:givenName Richard D.
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
287 rdf:type schema:Person
288 sg:person.0742751333.43 schema:affiliation grid-institutes:grid.410566.0
289 schema:familyName Rottey
290 schema:givenName Sylvie
291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742751333.43
292 rdf:type schema:Person
293 sg:person.07540360642.41 schema:affiliation grid-institutes:grid.411414.5
294 schema:familyName Peeters
295 schema:givenName Marc
296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07540360642.41
297 rdf:type schema:Person
298 sg:person.07541362455.51 schema:affiliation grid-institutes:grid.418786.4
299 schema:familyName Chapman
300 schema:givenName Sonya
301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07541362455.51
302 rdf:type schema:Person
303 sg:person.0754516716.49 schema:affiliation grid-institutes:grid.489173.0
304 schema:familyName Falchook
305 schema:givenName Gerald S.
306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754516716.49
307 rdf:type schema:Person
308 sg:person.07670550366.33 schema:affiliation grid-institutes:grid.417540.3
309 schema:familyName Zhang
310 schema:givenName Wei
311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07670550366.33
312 rdf:type schema:Person
313 sg:pub.10.1038/s41598-017-18433-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100203108
314 https://doi.org/10.1038/s41598-017-18433-4
315 rdf:type schema:CreativeWork
316 sg:pub.10.1186/s13046-019-1357-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1120498622
317 https://doi.org/10.1186/s13046-019-1357-y
318 rdf:type schema:CreativeWork
319 sg:pub.10.1186/s13046-019-1409-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1120996560
320 https://doi.org/10.1186/s13046-019-1409-3
321 rdf:type schema:CreativeWork
322 sg:pub.10.1186/s40425-017-0257-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1090453966
323 https://doi.org/10.1186/s40425-017-0257-y
324 rdf:type schema:CreativeWork
325 sg:pub.10.1186/s40425-018-0435-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109887636
326 https://doi.org/10.1186/s40425-018-0435-6
327 rdf:type schema:CreativeWork
328 sg:pub.10.2165/11596370-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002877462
329 https://doi.org/10.2165/11596370-000000000-00000
330 rdf:type schema:CreativeWork
331 grid-institutes:None schema:alternateName Department of Medical Oncology, GZA Sint Augustinus, Oosterveldlaan, Wilrijk, Belgium
332 schema:name Department of Medical Oncology, GZA Sint Augustinus, Oosterveldlaan, Wilrijk, Belgium
333 rdf:type schema:Organization
334 grid-institutes:grid.17788.31 schema:alternateName The Faculty of Medicine, The Wohl Institute for Translational Medicine, Hadassah Medical Center, Jerusalem, Israel
335 schema:name Department of Oncology, Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel
336 The Faculty of Medicine, The Wohl Institute for Translational Medicine, Hadassah Medical Center, Jerusalem, Israel
337 rdf:type schema:Organization
338 grid-institutes:grid.21729.3f schema:alternateName Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons, New York, NY, USA
339 schema:name Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons, New York, NY, USA
340 rdf:type schema:Organization
341 grid-institutes:grid.240324.3 schema:alternateName Department of Medicine,Medical Oncology, NYU Langone Health, New York, NY, USA
342 schema:name Department of Medicine,Medical Oncology, NYU Langone Health, New York, NY, USA
343 rdf:type schema:Organization
344 grid-institutes:grid.410566.0 schema:alternateName Drug Research Unit, Universitair Ziekenhuis Gent, Corneel Heymanslaan, Ghent, Belgium
345 schema:name Drug Research Unit, Universitair Ziekenhuis Gent, Corneel Heymanslaan, Ghent, Belgium
346 rdf:type schema:Organization
347 grid-institutes:grid.411414.5 schema:alternateName Department of Oncology, University Antwerpen, Universitair Ziekenhuis Antwerpen, Drie Eikenstraat, Edegem, Belgium
348 schema:name Department of Oncology, University Antwerpen, Universitair Ziekenhuis Antwerpen, Drie Eikenstraat, Edegem, Belgium
349 rdf:type schema:Organization
350 grid-institutes:grid.413795.d schema:alternateName The Ella Institute for Immuno-Oncology, Sheba Medical Center, Oncology Institute, Tel Hashomer, Ramat Gan, Israel
351 schema:name The Ella Institute for Immuno-Oncology, Sheba Medical Center, Oncology Institute, Tel Hashomer, Ramat Gan, Israel
352 rdf:type schema:Organization
353 grid-institutes:grid.417540.3 schema:alternateName Eli Lilly and Company, Indianapolis, IN, USA
354 schema:name Eli Lilly and Company, Indianapolis, IN, USA
355 rdf:type schema:Organization
356 grid-institutes:grid.418786.4 schema:alternateName Eli Lilly and Company, Windlesham, Surrey, UK
357 schema:name Eli Lilly and Company, Windlesham, Surrey, UK
358 rdf:type schema:Organization
359 grid-institutes:grid.419466.8 schema:alternateName Comprehensive Cancer Care Department – Faculty of Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
360 schema:name Comprehensive Cancer Care Department – Faculty of Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
361 rdf:type schema:Organization
362 grid-institutes:grid.428633.8 schema:alternateName Hematologic Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA
363 schema:name Hematologic Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA
364 rdf:type schema:Organization
365 grid-institutes:grid.489173.0 schema:alternateName Drug Development Unit, Sarah Cannon Research Institute at HealthONE, 1800 Williams St Ste 300, Denver, CO, USA
366 schema:name Drug Development Unit, Sarah Cannon Research Institute at HealthONE, 1800 Williams St Ste 300, Denver, CO, USA
367 rdf:type schema:Organization
368 grid-institutes:grid.492963.3 schema:alternateName Department of Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
369 schema:name Department of Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
370 rdf:type schema:Organization
371 grid-institutes:grid.6451.6 schema:alternateName Technion – Israel Institute of Technology, Haifa, Israel
372 schema:name Department of Oncology, Clinical Research Institute at Rambam, Rambam Medical Center, Haifa, Israel
373 Technion – Israel Institute of Technology, Haifa, Israel
374 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...